The Trump administration recently cancelled billions of dollars in funding to the NIH. Healthcare experts say the funding ...

About 90% of healthcare organizations are insecurely connected to the internet and running systems vulnerable to exploitation ...

Novo Nordisk has been on the hunt for differentiated obesity drugs that could complement its blockbuster GLP-1 agonist, Wegovy. It’s found a contender with preclinical data indicating it can ...

Editor’s note: This story is based on discussions at Abarca Forward, a conference in San Juan, Puerto Rico, hosted by Abarca Health, a pharmacy benefit manager. MedCity News was invited to ...

Amid the market volatility and intense macroeconomic uncertainty, is it wise for Hinge Health to test the public markets?

Quest Diagnostics teamed up with Google Cloud. The collaboration seeks to deliver new AI capabilities — including predictive ...

Hospitals started 2025 with a stable financial performance driven by strong patient volumes, but rising costs for drugs, ...

A month before 23andMe’s bankruptcy filing, CEO Anne Wojcicki had a fully financed proposal to take the genetic testing ...

Obesity has many drivers, but for those with a particular rare metabolic disorder, the root cause is genetic. These patients develop ravenous hunger unsatisfied by any amount of food. The constant ...

For the first time, traditional drug spending has exceeded specialty drug spending, largely due to the demand for GLP-1s, according to a new report from Evernorth Research Institute. Evernorth ...